Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration

While results thus far demonstrate the clinical benefit of trastuzumab, some patients do not respond to this therapy. To identify a molecular predictor of trastuzumab benefit, we conducted whole-transcriptome analysis of primary HER2+ breast carcinomas obtained from patients treated with trastuzumab...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Triulzi, Tiziana, De Cecco, Loris, Sandri, Marco, Prat, Aleix, Giussani, Marta, Paolini, Biagio, Carcangiu, Marialuisa L., Canevari, Silvana, Bottini, Alberto, Balsari, Andrea, Menard, Sylvie, Generali, Daniele, Campiglio, Manuela, Di Cosimo, Serena, Tagliabue, Elda
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2015
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4695052/
https://ncbi.nlm.nih.gov/pubmed/26334217
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items